The FDA approved on Wednesday Tecfidera (dimethyl fumarate) made by Biogen Idec as the third oral agent for the treatment of multiple sclerosis. European regulators have also recommended its approval. Tecfidera was shown to cut the relapse rate by 44% in one trial and 53% in another and is taken twice daily. Although multiple daily doses can limit its compliance compared to once-daily agents including Gilenya and Aubagio, Tecfidera appears to have fewer restrictions and monitoring requirements (for heart, liver and eye complications) compared to those agents. What are your thoughts about newly approved oral agent for multiple sclerosis?

For additional information, click here